BIO Patient and Health Advocacy Summit Hosts Over 300 Attendees from Wide Range of Health Care Organizations
Washington, D.C. (November 4, 2016) – The fifth annual BIO Patient and Health Advocacy Summit concluded today, bringing together 300 attendees representing over 200 organizations from patient advocacy, health care providers, academia, government, think tanks, professional societies and the biotechnology industry. The event provides a forum for lively discussions on timely health policy issues and best practices. Organized by the Biotechnology Innovation Organization (BIO), the event’s educational programming was designed to encourage thought-provoking discussion and to advance partnerships among stakeholders in the healthcare space.
“This BIO patient advocacy summit has grown to include vastly diverse patient advocacy organizations on an international level. Patients’ perspectives are integral in the research and development of new treatment options,” said Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Chair of BIO’s Patient Advocacy Committee. “We look to continually engage with patient groups with strict adherence to BIO’s Guidelines for Patient Engagement to find innovative ways to incorporate all patients’ voices into the development of life-saving treatments. For the past five years, the Summit has provided an open forum for building invaluable partnerships among all stakeholders in the healthcare ecosystem.”
The Summit’s opening keynote luncheon began with remarks from Hastings and was followed by a town hall-style discussion that explored the potential implications of the upcoming Presidential and congressional races for health care delivery and access.
Other deliberations throughout the conference centered on the patient’s voice in the reauthorization of the Prescription Drug User Fee Act (PDUFA VI), patient perspectives in the development of value assessment frameworks, collaborations to incorporate patient perspectives throughout the life cycle of drug development and best practices around engagement with the provider and payor communities.
The BIO Patient and Health Advocacy Summit is possible thanks to the generous support of our sponsors, including Champion Sponsors: Astellas, Bristol-Myers Squibb, Celgene, Genentech, Eli Lilly and Company, Shire and Takeda Oncology; Ally Sponsors: Alkermes, Amgen, Biogen, Merck and Novo Nordisk; and Supporting Sponsors: Alexion, EMD Serono, Grifols, Novartis, Pfizer, Sanofi Genzyme, Sarepta, UCB and Vertex.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
November 7-9, 2016
BIO CEO & Investor Conference
February 13-14, 2017
New York, New York
BIO Asia International Conference
March 14-15, 2017
BIO International Convention
June 19-22, 2017
San Diego, California